EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model

Ayşe Çakır Gündoğdu, Neziha Senem Arı, Ahmet Koçak, Gülnihal Şenol, Asiye Höbel, Ömer Eldiven, Fatih Kar, Orhan Özatik

Biomolecules and Biomedicine · 30.06.2025 · 25 (11) · 2558-2569

DOI: 10.17305/bb.2025.12676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 30.06.2025. Verfasst von Ayşe Çakır Gündoğdu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Embryology, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Türkiye. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Letrozole, Pyridones, Ovary. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterized by cystic ovarian morphology, anovulation, and infertility. Ovarian fibrosis has recently emerged as a key pathological feature of PCOS. This study investigated whether pirfenidone (PFD), an antifibrotic agent, could improve ovarian dysfunction in a letrozole-induced PCOS rat model. Forty-two female Wistar albino rats were divided into six groups (n=7 each): control, PFD, PCOS, PCOS/PFD, PCOS/combined oral contraceptives (COC), and PCOS/PFD/COC. PCOS was induced using letrozole (1 mg/kg/day orally for 21 days). PFD (200 mg/kg/day) and/or COC (0.18 mg/kg cyproterone acetate and 0.00315 mg/kg ethinyl estradiol) were administered for 21 days. Compared to controls, PCOS rats exhibited significant disruptions in estrous cyclicity, ovarian morphology, and fibrosis-related markers (all p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeLetrozolePyridonesOvaryAnimalsFemaleRatsRats, WistarFibrosisDisease Models, AnimalMatrix Metalloproteinase 2

Substanzen

LetrozolePyridonespirfenidoneMatrix Metalloproteinase 2

Autor:innen und Institutionen

  • Department of Histology and Embryology, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Türkiye.
  • Department of Medical Biochemistry, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Türkiye.

Zitieren

APA

Çakır Gündoğdu, A., Arı, N. S., Koçak, A., Şenol, G., Höbel, A., Eldiven, Ö., Kar, F., & Özatik, O. (2025). Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model. Biomolecules and Biomedicine, 25(11), 2558-2569. https://doi.org/10.17305/bb.2025.12676

Vancouver

Çakır Gündoğdu A, Arı NS, Koçak A, Şenol G, Höbel A, Eldiven Ö, et al. Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model. Biomolecules and Biomedicine. 2025;25(11):2558-2569. doi:10.17305/bb.2025.12676

BibTeX
@article{akrGndodu2025,
  author = {Çakır Gündoğdu, Ayşe and Arı, Neziha Senem and Koçak, Ahmet and Şenol, Gülnihal and Höbel, Asiye and Eldiven, Ömer and Kar, Fatih and Özatik, Orhan},
  title = {Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model},
  journal = {Biomolecules and Biomedicine},
  year = {2025},
  volume = {25},
  number = {11},
  pages = {2558--2569},
  doi = {10.17305/bb.2025.12676}
}
Kostenlos starten →